论文部分内容阅读
目的观察莫西沙星对清除早发医院获得性肺炎病原菌的作用。方法选取早发且无多重耐药危险因素的医院获得性肺炎患者60例,随机分为两组,莫西沙星组30例,予盐酸莫西沙星氯化钠注射液(莫西沙星0.4g加入0.9%氯化钠注射液250mL中)静脉滴注,1日1次,连用7d,头孢曲松组30例,予头孢曲松钠针剂2.0g加入0.9%氯化钠注射液250mL中静脉滴注,1日1次,连用7d,观察病原菌清除率。结果治疗后病原菌清除率莫西沙星组优于头孢曲松组,差异显著(P<0.05)。结论莫西沙星针剂治疗早发且无多重耐药危险因素的医院获得性肺炎具有较好的病原菌清除率,是较理想的药物之一。
Objective To observe the effect of moxifloxacin on the eradication of pathogenic bacteria in hospital-acquired pneumonia. Methods Sixty patients with nosocomial pneumonia who had no risk of multiple drug resistance and who had developed early were randomly divided into two groups. Moxifloxacin group (n = 30), moxifloxacin hydrochloride and sodium chloride injection (moxifloxacin 0.4g) 0.9% sodium chloride injection 250mL) intravenously, once a day, once every 7 days, ceftriaxone group 30 cases, to ceftriaxone sodium injection 2.0g 0.9% sodium chloride injection 250mL intravenous infusion , 1 on the 1st, once every 7d, observe the clearance rate of pathogens. Results After treatment, the clearance rate of pathogenic bacteria in moxifloxacin group was superior to that in ceftriaxone group (P <0.05). Conclusion Moxifloxacin injection for hospital-acquired pneumonia is an ideal drug for the treatment of hospital-acquired pneumonia with early-onset and no multi-drug resistance risk factors.